
MapLight Therapeutics Announces $372.5 Million Series D Financing
MapLight Therapeutics announced an oversubscribed $372.5 million Series D financing. The financing was co-led by Forbion and Life Sciences at Goldman Sachs Alternatives, with participation from additional new